Related Experiment Video
Updated: Aug 17, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
Published on: October 17, 2019
L-656,575 (OCP-9-176): a novel oxacephem. In vitro activity against aerobic and anaerobic clinical bacterial isolates
B Weissberger1, G K Abruzzo, R A Fromtling
1Department of Basic Microbiology, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey 07065-0900.
Abstract:
L-656,575 (OCP-9-176) is a novel oxacephem superior to ceftazidime in in vitro activity against clinical isolates of Enterobacter species, methicillin-susceptible Staphylococcus aureus and Staphylococcus epidermidis, and multiply-resistant Pseudomonas aeruginosa. Our results suggest that L-656,575 has a high affinity for penicillin binding proteins of Pseudomonas and may bind preferentially to PBP-3 in this organism. L-656,575 is active against beta-lactamase derepressed Enterobacteriaceae and ceftazidime-resistant P. aeruginosa.
Related Concept Videos
Antibiotic Selection
Antimicrobial Effectiveness
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Bacterial DNA Synthesis
Clinical Significance of Antibiotic Resistance

